Indicated in adults aged 18 years and older with type 2 diabetes mellitus: to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control when already being treated with the free combination of empagliflozin and linagliptin

Medicine details

Medicine name:
empaglifozin linagliptin fixed-dose combination (Glyxambi)
Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Endocrine system
Submission type
Abbreviated submission
Advice due date:
SMC meeting date:
04 April 2017